271 related articles for article (PubMed ID: 27135195)
1. Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.
Vauquelin G
Br J Clin Pharmacol; 2016 Sep; 82(3):673-82. PubMed ID: 27135195
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E
Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812
[TBL] [Abstract][Full Text] [Related]
3. On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.
Vauquelin G
Expert Opin Drug Discov; 2015 Oct; 10(10):1085-98. PubMed ID: 26165720
[TBL] [Abstract][Full Text] [Related]
4. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Azizi M; Bissery A; Lamarre-Cliche M; Ménard J
Hypertension; 2004 Apr; 43(4):785-90. PubMed ID: 15023936
[TBL] [Abstract][Full Text] [Related]
5. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
6. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Morsing P
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S248-54. PubMed ID: 9892173
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.
Fuchs B; Breithaupt-Grögler K; Belz GG; Roll S; Malerczyk C; Herrmann V; Spahn-Langguth H; Mutschler E
J Pharm Pharmacol; 2000 Sep; 52(9):1075-83. PubMed ID: 11045887
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier M; Buclin T; Biollaz J; Nussberger J; Waeber B; Brunner HR
Kidney Int Suppl; 1996 Jun; 55():S24-9. PubMed ID: 8743506
[No Abstract] [Full Text] [Related]
9. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of candesartan.
Gleiter CH; Mörike KE
Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
Azizi M; Chatellier G; Guyene TT; Ménard J
J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
[TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil: an update of its use in essential hypertension.
Easthope SE; Jarvis B
Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].
Kusumoto K; Mori M; Tanokashira J; Totsuka N
Nihon Yakurigaku Zasshi; 2009 Oct; 134(4):217-24. PubMed ID: 19828927
[No Abstract] [Full Text] [Related]
18. Candesartan cilexetil: an angiotensin II-receptor blocker.
See S; Stirling AL
Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
[TBL] [Abstract][Full Text] [Related]
19. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Cernes R; Mashavi M; Zimlichman R
Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]